Alternative names:
SARS-CoV-2 Delta variant

Specifications for
PepTivator
®
SARS-CoV-2 Prot_S B.1.617.2

Overview

Stimulate T cells reactive to the spike protein of the SARS-CoV-2 B.1.617.2 lineage (Delta variant) using PepTivator Peptide Pools. PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. The PepTivator SARS-CoV-2 Prot_S B.1.617.2 Mutation Pool covers selectively the mutated regions in the surface or spike glycoprotein (“S”) of the SARS-CoV-2 B.1.617.2 lineage (Delta variant), one of the subvariants of B.1.617. PepTivator SARS-CoV-2 Prot_S B.1.617.2 WT Reference Pool consists of the 32 homologous peptides of the Wuhan sequence and serves as a control.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Alternative names

SARS-CoV-2 Delta variant

Detailed product information

Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was first detected in December 2019 in Wuhan, China. Since that time the virus kept mutating, leading to new virus variants. The B.1.617.2 lineage, also known Delta variant, as G/452R.V3, “double mutant” (T478K+L452R) or VUI-21APR-02, is a SARS-CoV-2 subvariant that was first discovered in India in December 2020. The mutations of this variant affect also immune-relevant parts of structural SARS-CoV-2 proteins and the respective sequences are available in GISAID, a genome data base. The mutations listed below are taken from sequence EPI_ISL_1718882. The B.1.617.2 lineage (Delta variant) has been found to evade a pre-existing antibody response and appears to be more infectious than other variants.
In total there are 10 mutations in the surface or spike glycoprotein (“S”) of the B.1.617.2 lineage (Delta variant) compared to the Wuhan variant (reference genome GenBank MN908947.3): T19R, G142D, E156G, deletion 157, deletion 158, L452R, T478K, D614G, P681R, and D950N. This subvariant lacks the E484Q mutation.
The PepTivator SARS-CoV-2 Prot_S B.1.617.2 Mutation Pool covers selectively the mutated regions. It consists of 32 peptides of 15 aa length. The PepTivator SARS-CoV-2 Prot_S B.1.617.2 Mutation Pool can be used to supplement PepTivators covering the sequence of the wild-type spike glycoprotein (“S”) in order to detect immune responses towards both variants, Wuhan (wild type) variant and B.1.617.2 lineage (Delta variant). PepTivator Peptide pools spanning the sequence of the spike glycoprotein (“S”) of the Wuhan (wild-type) variant are PepTivator SARS-CoV-2 Prot_S (predicted immunodominant sequence domains), Prot_S1 (N-terminal S1 domain), Prot_S+ (part of the C-terminal S2 domain) and Prot_S Complete (all functional domains).
The PepTivator SARS-CoV-2 Prot_S B.1.617.2 WT Reference Pool consists of the 32 homologous peptides of the Wuhan sequence and covers T19, G142, E156, F157, R158, L452, T478, D614, P681,
and D950 of the Wuhan variant (reference genome GenBank MN908947.3). PepTivator SARS-CoV-2 Prot_S B.1.617.2 WT Reference Pool serves as a control for the SARS-CoV-2 Prot_S B.1.617.2 Mutation Pool. Comparison of the T cell immune response upon stimulation with mutation and reference pool can be used to analyze mutation specific T cell responses.

Applications

The in vitro stimulation of SARS-CoV-2-specific CD4
+
and CD8
+
T cells with PepTivators causes secretion of effector cytokines and upregulation of activation markers, which then allow the detection and isolation of SARS-CoV-2–specific T cells:
  • Detection and analysis of antigen-specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable antigen-specific CD4+ T cells with the CD154 MicroBead Kit, or of viable CD4+ and CD8+ T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation antigen-specific CD4+ and CD8+ effector/memory T cells from naive T cell populations.
  • Pulsing of antigen-presenting cells e.g. for research on dendritic cell vaccination.

Resources for
PepTivator
®
SARS-CoV-2 Prot_S B.1.617.2

Related products for
PepTivator
®
SARS-CoV-2 Prot_S B.1.617.2

11 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?